'On standalone basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Supriya Lifescience has increased 20.31% to Rs 199.83 crore. Operating profit margin has declined from 38.96% to 36.36%, leading to 12.25% rise in operating profit to Rs 72.65 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 33.89% to 29.63%. Employee cost increased from 10.84% to 11.95%. Other expenses rose from 19.66% to 22.94%.
Other income up 8.33% to Rs 2.73 crore. PBIDT rose 12.11% to Rs 75.38 crore. Provision for interest fell 2.33% to Rs 0.42 crore. Loan funds declined from Rs 5.51 crore as of 30 September 2024 to Rs 5.23 crore as of 30 September 2025. Inventories rose to Rs 142.81 crore as of 30 September 2025 from Rs 107.99 crore as of 30 September 2024. &nbs...
Pleaselogin & subscribe to view the full report.
More Reports
-
(18-Jan-2026)
Yes Bank
Asset quality and margins improve, loan growth eases
-
(18-Jan-2026)
ICICI Bank
Bottomline hit by one off provisions
-
(18-Jan-2026)
HDFC Bank
Loan growth and margins improve, asset quality stable
-
(17-Jan-2026)
Federal Bank
Healthy all-round performance
|
|